PTEN and prostate cancer: In somatic cancers, such as endometrial, breast, prostate cancer, and glioblastoma, PTEN inactivation encompasses an array of mutations which include missense and nonsense mutations, mono or bi-allelic deletion of the genomic locus or silencing through promoter methylation, and also targeting by oncogenic microRNAs [9,10].